HOME >> BIOLOGY >> NEWS
Targeting the adrenal gland could be key strategy against heart failure, Jefferson scientists show

(PHILADELPHIA) Scientists at the Center for Translational Medicine at Thomas Jefferson University in Philadelphia have staved off heart failure in animals by using gene therapy to shut down the adrenal glands excessive output of fight or flight hormones such as epinephrine and norepinephrine. By blocking GRK2, an important regulatory enzyme, they cut the hormone production that forces the heart to pump too hard, leading to heart failure. Such a novel approach targeting the adrenal gland in addition to the heart provides a potential new strategy against heart failure, and could lead to a new class of drugs.

The researchers, led by Walter Koch, Ph.D., W.W. Smith Professor of Medicine and director of the Center for Translational Medicine in the Department of Medicine at Jefferson Medical College, report their findings February 18, 2007, in an advance online publication in the journal Nature Medicine.

The emphasis has always been in treating right at the heart, says Stephen B. Liggett, M.D., director of the cardiopulmonary genomics program at the University of Maryland School of Medicine, who has written an accompanying editorial. Despite our best efforts, about half of all heart failure patients die within five years of diagnosis, so clearly something new is needed. These results add a completely new dimension to the way physicians might be able to intervene to improve heart failure therapy. When an individuals heart begins to fail, the sympathetic nervous system, attempting to compensate for the weakened heart, goes into overdrive, pumping out increasing levels of stimulants catecholamines such as epinephrine and norepinephrine, making a bad situation worse. The typical treatment beta blockers inhibit the beta adrenergic receptors on the heart, blocking the hormones that force the heart to work overtime.

Dr. Kochs group focused instead on the source of catecholamines the adrenal gland. It discovered that in heart failure,
'"/>

Contact: Steve Benowitz
steven.benowitz@jefferson.edu
215-955-5291
Thomas Jefferson University
18-Feb-2007


Page: 1 2

Related biology news :

1. Targeting key proteins of carcinogenesis
2. Targeting tumors the natural way
3. Targeting tau: Inflammation study suggests new approach for fighting Alzheimers
4. Best of both worlds -- Targeting a single gene could inhibit bone decay and stimulate bone growth
5. Targeting wolbachia, doxycycline reduces pathology of lymphatic filariasis
6. Targeting lung cancer
7. Targeting the dosage compensation complex
8. Targeting pancreatic cancer
9. Targeting a key enzyme with gene therapy reversed course of Alzheimers disease in mouse models
10. Targeting tumor growth
11. How the adrenal clock keeps the body in synch

Post Your Comments:
(Date:5/17/2013)... MD (May 18, 2013) The AGA Research Foundation ... into the relationship between the gut microbiota, one of ... and disease. , The AGA Research Awards Panel ... from Massachusetts General Hospital and Harvard Medical School, Boston, ... recipient. Dr. Chan will receive $25,000 of funding, commencing ...
(Date:5/17/2013)... China---- Why Tibetan antelope can live at elevations ... collaborative research published in Nature Communications , ... provide evidence that some genetic factors may be ... environments. The data in this work will also ... the biology of other ruminant species. , The ...
(Date:5/16/2013)... (May 17, 2013) Illustrating a commitment to ... American Gastroenterological Association (AGA) Research Foundation has announced ... Research Fellowship Award recipients. Supported by the National ... (NIDDK), this new award helps underrepresented minority students ... and nutrition research. , "By establishing this new ...
Breaking Biology News(10 mins):New gut microbiome research to explore red meat -- colorectal cancer pathway 2The genome sequence of Tibetan antelope sheds new light on high-altitude adaptation 2Underrepresented minority students receive fellowships in digestive disease and nutrition research 2
(Date:5/20/2013)... , May 20, 2013   Flexion Therapeutics , ... W. Driscoll to its management team as ... years of financial management experience with biotechnology and medical ... Driscoll was chief financial officer for Novavax (NASDAQ: ... secured more than $250 million through a combination of ...
(Date:5/20/2013)... 20, 2013 Recognizing exciting and ... members to its 2013 Class of Young Professors. ... will provide this outstanding international group with more ... basic science to meet global challenges.     , The ... promising young and untenured research faculty working in ...
(Date:5/20/2013)... Culver City, CA (PRWEB) May 20, 2013 ... Trustees has announced the appointment of Lisa Baird as ... WMIS on July 8, 2013. The WMIS ... multi-modal imaging applications to understand and effectively treat diseases ... Molecular Imaging Society (WMIS) was established in 2011 by ...
(Date:5/17/2013)... 2013 Dr. Sparano is Professor of ... at the Albert Einstein College of Medicine and Associate ... Medical Center. He is also Associate Director for ... the Einstein Breast Cancer Working Group, a multidisciplinary group ... research. He also serves as Vice Chair of the ...
Breaking Biology Technology:Flexion Therapeutics Names Frederick Driscoll Chief Financial Officer 2DuPont Celebrates Scientific Innovation by Recognizing Young Professors 2DuPont Celebrates Scientific Innovation by Recognizing Young Professors 3WMIS Appoints Lisa Baird as Next Executive Director 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 3
Cached News: